Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration (Q64253765)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30776910%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

4 references

26 April 2020

17 December 2020

18 December 2020

22 August 2022

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30776910%20AND%20SRC:MED&resulttype=core&format=json

biomedical investigative technique

24 April 2020

main subject

NHL

0 references

1 reference

19 September 2019

1 reference

ChEBI release 2020-05-28

1 reference

17 December 2020

1 reference

18 December 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30776910%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

author name string

Erik De Clercq

series ordinal

1

0 references

language of work or name

English

0 references

publication date

1 January 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30776910%20AND%20SRC:MED&resulttype=core&format=json

Antiviral Chemistry & Chemotherapy

24 April 2020

published in

7 references

22 June 2019

19 September 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30776910%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

26 April 2020

17 December 2020

18 December 2020

22 August 2022

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30776910%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

page(s)

2040206619829382

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30776910%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 4.0 International

24 April 2020

copyright license

6 references

22 June 2019

19 September 2019

26 April 2020

17 December 2020

18 December 2020

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event

22 August 2022

cites work

1 reference

12 December 2020

A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia

1 reference

12 December 2020

Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100

1 reference

12 December 2020

Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.

1 reference

12 December 2020

Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4

1 reference

12 December 2020

WHIM syndrome, an autosomal dominant disorder: clinical, hematological, and molecular studies

1 reference

12 December 2020

Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers

1 reference

12 December 2020

AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice.

1 reference

12 December 2020

Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences

1 reference

12 December 2020

Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease

1 reference

12 December 2020

The bicyclam AMD3100 story

1 reference

12 December 2020

Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist

1 reference

12 December 2020

"MYELOKATHEXIS"--A NEW FORM OF CHRONIC GRANULOCYTOPENIA. REPORT OF A CASE

1 reference

12 December 2020

CHRONIC IDIOPATHIC GRANULOCYTOPENIA.

1 reference

12 December 2020

Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence

1 reference

12 December 2020

The epidemiology of cholangiocarcinoma

1 reference

12 December 2020

Cancer and the chemokine network

1 reference

12 December 2020

CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers.

1 reference

12 December 2020

Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist

1 reference

12 December 2020

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

1 reference

12 December 2020

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma

1 reference

12 December 2020

Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects

1 reference

12 December 2020

Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution

1 reference

12 December 2020

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

1 reference

12 December 2020

Hepatopulmonary syndrome--a liver-induced lung vascular disorder

1 reference

12 December 2020

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

1 reference

12 December 2020

Differential mobilization of subsets of progenitor cells from the bone marrow

1 reference

12 December 2020

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

1 reference

12 December 2020

The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).

1 reference

12 December 2020

Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.

1 reference

12 December 2020

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

1 reference

12 December 2020

American Thyroid Association guidelines for management of medullary thyroid cancer: an adult endocrinology perspective

1 reference

12 December 2020

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

1 reference

12 December 2020

Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features

1 reference

12 December 2020

FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation

1 reference

12 December 2020

Chronic AMD3100 antagonism of SDF-1alpha-CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction

1 reference

12 December 2020

Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers

1 reference

12 December 2020

The genesis and evolution of high-grade serous ovarian cancer

1 reference

12 December 2020

AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome

1 reference

12 December 2020

Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma

1 reference

12 December 2020

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome

1 reference

12 December 2020

The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome

1 reference

12 December 2020

Rethinking ovarian cancer: recommendations for improving outcomes

1 reference

12 December 2020

SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion

1 reference

12 December 2020

The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor

1 reference

12 December 2020

Discovery of novel stem cell mobilizers that target the CXCR4 receptor

1 reference

12 December 2020

New hope for mobilization failures . . . again

1 reference

12 December 2020

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

1 reference

12 December 2020

Inhibition of stromal CXCR4 impairs development of lung metastases.

1 reference

12 December 2020

Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice

1 reference

12 December 2020

Hepatopulmonary syndrome: update on pathogenesis and clinical features

1 reference

12 December 2020

Halting metastasis through CXCR4 inhibition

1 reference

12 December 2020

CXCR4-mediated osteosarcoma growth and pulmonary metastasis is promoted by mesenchymal stem cells through VEGF.

1 reference

12 December 2020

CXCR7-mediated progression of osteosarcoma in the lungs.

1 reference

12 December 2020

Expression of the chemokine receptor CXCR7 in CXCR4-expressing human 143B osteosarcoma cells enhances lung metastasis of intratibial xenografts in SCID mice

1 reference

12 December 2020

Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations

1 reference

12 December 2020

International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors

1 reference

12 December 2020

A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

1 reference

12 December 2020

Silencing of CXCR4 inhibits tumor cell proliferation and neural invasion in human hilar cholangiocarcinoma

1 reference

12 December 2020

Intra-Arterial Immunoselected CD34+ Stem Cells for Acute Ischemic Stroke

1 reference

12 December 2020

Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine

1 reference

12 December 2020

Chromothriptic cure of WHIM syndrome

1 reference

12 December 2020

AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments

1 reference

12 December 2020

Probing the Molecular Interactions between CXC Chemokine Receptor 4 (CXCR4) and an Arginine-Based Tripeptidomimetic Antagonist (KRH-1636)

1 reference

12 December 2020

Plerixafor for stem cell mobilization: the current status

1 reference

12 December 2020

Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists

1 reference

12 December 2020

Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices

1 reference

12 December 2020

Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial

1 reference

12 December 2020

A Novel CXCR4 antagonist enhances angiogenesis via modifying the ischaemic tissue environment.

1 reference

12 December 2020

Functional and structural consequences of chemokine (C-X-C motif) receptor 4 activation with cognate and non-cognate agonists.

1 reference

12 December 2020

Impact of plerixafor (mozobil) on hospital efficiency: A single center experience

1 reference

12 December 2020

Current Use and Trends in Hematopoietic Cell Transplantation in the United States

1 reference

12 December 2020

Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice

1 reference

12 December 2020

Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer

1 reference

12 December 2020

AMD3100 Accelerates Reendothelialization of Neointima in Rabbit Saccular Aneurysm After Flow Diverter Treatment.

1 reference

12 December 2020

CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome

1 reference

12 December 2020

CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth.

1 reference

12 December 2020

Danshensu accelerates angiogenesis after myocardial infarction in rats and promotes the functions of endothelial progenitor cells through SDF-1α/CXCR4 axis

1 reference

12 December 2020

CXCR4 antagonist AMD3100 elicits analgesic effect and restores the GlyRα3 expression against neuropathic pain

1 reference

12 December 2020

Low-dose photon irradiation induces invasiveness through the SDF-1α/CXCR4 pathway in malignant mesothelioma cells

1 reference

12 December 2020

Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency.

1 reference

12 December 2020

CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma

1 reference

12 December 2020

A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination

1 reference

12 December 2020

The chemokine receptor type 4 antagonist, AMD3100, interrupts experimental tooth movement in rats

1 reference

12 December 2020

Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell

1 reference

12 December 2020

AMD3100 treatment attenuates pulmonary angiogenesis by reducing the c-kit (+) cells and its pro-angiogenic activity in CBDL rat lungs

1 reference

12 December 2020

AMD3100 inhibits brain-specific metastasis in lung cancer via suppressing the SDF-1/CXCR4 axis and protecting blood-brain barrier

1 reference

12 December 2020

Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.

1 reference

12 December 2020

CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation

1 reference

12 December 2020

Targeting the CXCL12/CXCR4 Pathway and Myeloid Cells to Improve Radiation Treatment of Locally Advanced Cervical Cancer.

1 reference

12 December 2020

CXCR4-CXCL12 interaction is important for plasma cell homing and survival in NZB/W mice

1 reference

12 December 2020

CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver

1 reference

12 December 2020

Inhibition of HIV fusion by small molecule agonists through efficacy-engineering of CXCR4.

1 reference

12 December 2020

Identifiers

DOI

10.1177/2040206619829382

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30776910%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30776910%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

PubMed publication ID

30776910

1 reference